BridgeBio Pharma(NASDAQ) BBIO

BridgeBio helps people with rare genetic diseases by creating medicines that target the source of their conditions. The company finds new treatments and moves them quickly through testing to reach patients who have few other options. These medicines focus on solving life-altering health problems for both children and adults.

What BridgeBio Makes

• Attruby (acoramidis): Oral medicine for adults with a heart condition called transthyretin amyloid cardiomyopathy; generated $362.4 million in U.S. net product revenue in 2025.
• Beyonttra (acoramidis): Licensed treatment for heart disease in Europe and Japan; generated $105 million in license and service revenue in 2025.
• Late-Stage Programs: Investigational therapies for rare conditions including achondroplasia, a form of short stature, and limb-girdle muscular dystrophy.
• Early Discovery Pipeline: Research projects focused on genetic drivers in oncology and gene therapy for underserved patient populations.

Recent Growth and Partnerships

• Entered into an exclusive license agreement with Bayer in March 2024 to commercialize acoramidis in Europe.
• Received regulatory approvals for acoramidis in Europe, Japan, and the United Kingdom during the first half of 2025.
• Spun out BridgeBio Oncology Therapeutics to focus on cancer treatments, which became a public company in August 2025.
• Partnered with Alexion to develop and sell Beyonttra in the Japanese market.

A New Way to Build Medicines

The company uses a hub-and-spoke model that separates shared business functions from small, specialized scientific teams. This structure allows BridgeBio to fund many different programs at once and move resources quickly to the most successful projects.

The 2025 Scorecard

• Revenue reached $154.2 million in Q4 2025, up 2521% year-over-year from $5.9 million in Q4 2024.
• Net loss narrowed to $197.2 million in Q4 2025, a 25.6% improvement compared to the $265.1 million loss in Q4 2024.
• Free cash flow was negative $61 million in Q4 2025, up 69.3% from negative $198.6 million in Q4 2024.
• Market capitalization grew to $15.1 billion by the end of 2025, up 190.2% from $5.2 billion the previous year.

Bottom Line

BridgeBio has transformed from a research-focused startup into a commercial-stage firm with multiple approved drugs and a deep late-stage pipeline. Its efficient operating model supports the simultaneous development of dozens of therapies for rare genetic diseases.